Loading clinical trials...

Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease | Clinical Trials | Clareo Health

TERMINATEDNA

Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease

NCT03487380•Nantes University Hospital

View on ClinicalTrials.gov

Summary

The objective of the study is to highlight a modification of the composition of the intestinal microbiota associated with the diagnosis of Alzheimer's disease and its most unfavorable form, Rapid Cognitive Decline (DCR). This identification could lead to diagnostic strategies based on the analysis of the intestinal microbiome, and preventive and curative treatments, based on the modulation of intestinal microbiota

Eligibility

Age

70 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For Alzheimer groups without DCR and Alzheimer with DCR:
•patients between 70 and 90 years old
•with mild to moderate Alzheimer's disease (MMSE\> 15/30),
•followed in the CMRR of the University Hospital of Nantes or Angers
•having given their informed consent
•For the control group (non-Alzheimer's)
•more patients between 70 and 90 years
•consultant for a subjective memory complaint isolated at the CMRR of Nantes or Angers University Hospital,
•having given their informed consent

Exclusion Criteria

•Major patients under tutorship, curatorship or safeguard of justice
•Cognitive disorders possibly related to a metabolic or psychiatric cause
•History of prescription of antibiotic treatment in the last month
•History of acute gastrointestinal illness in the last month
•History of hospitalization for an acute medical pathology or for a surgical procedure in the last month

Locations (2)

CHU de Angers

Angers, France

CHU de Nantes

Nantes, France

Key Dates

Start Date

September 4, 2017

Primary Completion Date

June 12, 2023

Completion Date

June 12, 2023

Last Updated

February 1, 2024

Enrollment

ACTUAL participants

Conditions

Alzheimer DiseaseIntestinal Microbiota

Interventions

Fecal sample collection

PROCEDURE

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease